Ernexa Therapeutics (ERNAW) Capital Expenditures (2010 - 2026)

Ernexa Therapeutics has reported Capital Expenditures for 17 years, with the latest figure at $2000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $2000.0; the trailing twelve-month figure through Mar 2026 stood at $36000.0 (changed N/A YoY), and the FY2025 full-year result was $37000.0, down 89.97% from the prior year.
• Capital Expenditures for Q1 2026 stood at $2000.0, down from $15000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $249000.0 in Q2 2024, with the low at $2000.0 in Q1 2026.
• Historically, Capital Expenditures has averaged $70200.0 across 5 years, with a median of $32000.0 in 2022.
• The largest YoY upside for Capital Expenditures was 100.09% in 2022 against a maximum downside of 99.81% in 2022.
• Ernexa Therapeutics' Capital Expenditures stood at $21000.0 in 2022, then fell by 9.52% to $19000.0 in 2023, then changed by 0.0% to $19000.0 in 2024, then retreated by 21.05% to $15000.0 in 2025, then slumped by 86.67% to $2000.0 in 2026.
• The last three Capital Expenditures figures came in at $2000.0 (Q1 2026), $15000.0 (Q4 2025), and $19000.0 (Q3 2024), per Business Quant data.